Comparison of Healing Measures Tibial Fractures Following Standard Intramedullary Nailing or Micromotion Tibial Intramedullary Nailing
Launched by UNIVERSITY OF ALABAMA AT BIRMINGHAM · Nov 6, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is designed to compare two different methods for treating tibial fractures, which are breaks in the shinbone. The study will look at how well these methods help the bone heal and how patients feel after the surgery. One method uses a standard intramedullary nail, while the other uses a new type of nail called a micromotion tibial nail. The goal is to see which method leads to better healing and overall recovery for patients.
To participate in this trial, individuals need to be between the ages of 18 and 85 and have a stable tibial fracture that requires surgery. However, certain people may not be eligible, including those with specific types of unstable fractures, those who have had previous surgeries on the same leg, or those with certain health issues. Participants can expect to undergo surgery and will be closely monitored to track their healing process and any outcomes after the procedure. The trial is not yet recruiting participants, but it aims to provide valuable information to improve treatment for tibial fractures in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age 18 - 85 years
- • Stable Tibial fracture recommended for surgical intervention
- Exclusion Criteria:
- • Patients not meeting inclusion criteria
- • Unstable fracture patterns e.g. those needing a secondary intervention - masquelet/cement spacer)
- • Previously non-ambulatory patients
- • Delayed presentation of fracture (\>4 weeks)
- • Fractures that the treating surgeon indicates requires additional fixation strategies to achieve stability
- • Patients with an achieve infection or wound at the surgical site
- • Any previous ligament or fracture surgery on the index site
- • Inflammatory rheumatic disease or other rheumatic disease-
- • Immune compromised patients (hepatitis, HIV, etc.)
- • Unwilling or unable to participate or follow study protocol
About University Of Alabama At Birmingham
The University of Alabama at Birmingham (UAB) is a prominent academic institution and research hub dedicated to advancing healthcare through innovative clinical trials. Renowned for its commitment to medical discovery and education, UAB conducts cutting-edge research across a wide array of disciplines, including oncology, cardiology, neurology, and public health. With a robust infrastructure for clinical research, UAB fosters collaboration among interdisciplinary teams, leveraging state-of-the-art facilities and resources to enhance the translation of scientific findings into effective treatments and interventions. As a leader in clinical research, UAB aims to improve patient outcomes and contribute to the broader medical community through rigorous trial design and implementation.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Birmingham, Alabama, United States
Patients applied
Trial Officials
Joseph Johnson, MD
Principal Investigator
University of Alabama at Birmingham
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported